



HAL
open science

Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias.

Sarah Fernandes, Harold V.M. van Rijen, Virginie F. Forest, Stéphane Evain, Anne-Laure Leblond, Jean Mérot, Flavien Charpentier, Jacques M.T. de Bakker, Patricia F. Lemarchand

► **To cite this version:**

Sarah Fernandes, Harold V.M. van Rijen, Virginie F. Forest, Stéphane Evain, Anne-Laure Leblond, et al.. Cardiac cell therapy: overexpression of connexin43 in skeletal myoblasts and prevention of ventricular arrhythmias.: Cardiac cell and Cx43-gene therapy for arrhythmias. *Journal of Cellular and Molecular Medicine*, 2009, 13 (9B), pp.3703-12. 10.1111/j.1582-4934.2009.00740.x . inserm-00369695

HAL Id: inserm-00369695

<https://inserm.hal.science/inserm-00369695>

Submitted on 15 Mar 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1
2
3
4
5
6 **Cardiac Cell Therapy: Overexpression of Connexin43 in Skeletal Myoblasts**
7
8
9 **and Prevention of Ventricular Arrhythmias**
10
11
12
13

14 **Sarah Fernandes^{1,2}, Harold V.M. van Rijen³, Virginie Forest^{1,2}, Stéphane**
15 **Evain^{1,2,4}, Anne-Laure Leblond^{1,2}, Jean Mérot^{1,2,5}, Flavien Charpentier^{1,2,5},**
16 **Jacques M.T. de Bakker^{3,6}, Patricia Lemarchand^{1,2,4,*}.**
17
18
19
20
21
22
23
24

25 ¹ INSERM, UMR915, l'institut du thorax, IFR26, Nantes, France
26

27 ² Université de Nantes, *UFR Médecine*, Nantes, France
28

29 ³ Department of Medical Physiology, University Medical Center Utrecht, Utrecht, The
30 Netherlands
31
32

33 ⁴ CHU Nantes, l'institut du thorax, Nantes, France
34

35 ⁵ CNRS, ERL3147, Nantes, France
36
37

38 ⁶ Department of Experimental Cardiology, Academic Medical Center, Amsterdam, The
39 Netherlands
40
41
42

43
44 Short title: Cardiac cell and Cx43-gene therapy for arrhythmias
45
46
47
48
49
50

51 *Correspondence should be addressed to P.L. (patricia.lemarchand@univ-nantes.fr)
52

53 INSERM UMR915, l'institut du thorax, Faculté de Médecine, 1 rue Gaston Veil, F-
54 44035 Nantes cedex 1, France
55

56
57 Tel: (33) 2 40 41 29 91 Fax: (33) 2 40 41 29 50
58
59
60

ABSTRACT

Cell-based therapies have great potential for the treatment of cardiovascular diseases. Recently, using a transgenic mouse model Roell *et al.* reported that cardiac engraftment of connexin43-overexpressing myoblasts *in vivo* prevents post-infarct arrhythmia, a common cause of death in patients following heart attack [*Nature* 2007; 450: 819-24]. We carried out a similar study but in a clinically relevant context via transplantation of autologous connexin43-overexpressing myoblasts in infarcted rats. Seven days after coronary ligation, rats were randomized into 3 groups: a Control group injected with myoblasts, a Null group injected with myoblasts transduced with an empty lentivirus vector (Null), and a Cx43 group injected with myoblasts transduced with a lentivirus vector encoding connexin43. In contrast to Roell's report, arrhythmia occurrence was not statistically different between groups (58%, 64% and 48% for the Control (n=12), Null (n= 14) and Cx43 (n=23) -groups, respectively, p=0.92). Using *ex vivo* intramural monophasic action potential recordings synchronous electrical activity was observed between connexin43-overexpressing myoblasts and host cardiomyocytes, whereas such synchrony did not occur in the Null-transduced group. This suggests that *ex vivo* connexin43 gene transfer and expression in myoblasts improved intercellular electrical coupling between myoblasts and cardiomyocytes. However, in our model such electrical coupling was not sufficient to decrease arrhythmia induction. Therefore, we would suggest a note of caution on the use of combined Cx43 gene and cell therapy to prevent post-infarct arrhythmias in heart failure patients.

Keywords: cell therapy, gene therapy, arrhythmia, connexin43, myoblast

INTRODUCTION

The hypothesis behind cell-based therapy for cardiac injury is that adding healthy cells to injured myocardium increases the rate of recovery and, in so doing, improves cardiac function and prevents life-threatening arrhythmias, the major cause of sudden death in heart failure patients. Yet, to date, success with cell therapies has been limited, and under some conditions, such therapy results in arrhythmias, a documented risk of skeletal muscle myoblast delivery into the heart[1]. The exact mechanism of these arrhythmias is unknown, but it has been suggested that they result from a lack of electrical coupling between the skeletal myoblasts and the host cardiomyocytes[2].

Electrical coupling between ventricular cardiomyocytes is very efficient in healthy myocardium, and depends mainly on Connexin43 expression (Cx43, the primary ventricular gap junction protein). Interestingly, proliferating myoblasts express Cx43 but down-regulate Cx43 expression progressively upon fusion, mature skeletal myofiber (myotube) formation and further differentiation. Several preclinical and clinical studies have shown that once injected into the heart, myoblasts differentiate into myotubes, and thus, are not coupled to neighboring cardiomyocytes[3,4]. Interestingly, transplanted myotubes are able to contract spontaneously occasionally, but these contractions do not spread to neighboring cardiomyocytes[2]. *In vitro* and *ex vivo* studies have shown that a mixture of myotubes and cardiomyocytes without sufficient functional gap junctions results in slower conduction velocities and greater tissue heterogeneity[5,6]. Such heterogeneity predisposes to wave breaks and reentry, both key elements for inducing ventricular arrhythmias[7].

Recently, in a well-designed study using an *in vivo* infarcted mouse model, Roell *et al.* showed that cardiac transplantation of myoblasts from transgenic mice overexpressing

1
2
3 connexin43 (Cx43, the main cardiac gap junction protein) not only eliminates
4
5 myoblast pro-arrhythmogenic effect but also provides potent protection against
6
7 ventricular arrhythmias[8]. They concluded that an increase in intercellular coupling
8
9 by cell-based therapy may be an effective therapy to prevent post-infarction
10
11 ventricular arrhythmias[8].
12
13

14
15 In a previous study[9], we transplanted autologous myoblasts or autologous bone
16
17 marrow cells into infarcted heart of Wistar rats. Like Roell *et al*, using *in vivo*
18
19 programmed electrical stimulation (PES), we showed that transplantation of myoblasts
20
21 but not of bone marrow mononuclear cells increases arrhythmia induction. As a follow
22
23 up, the purpose of this new study was to evaluate arrhythmogenicity after autologous
24
25 cell therapy and Cx43 *ex vivo* gene transfer. This combination of cells and genes
26
27 represents a clinically relevant and pragmatic approach to Roell's hypothesis. Despite
28
29 electrical coupling between transplanted cells and host cardiomyocytes (as
30
31 demonstrated by Roell and confirmed in our study), we did not observe any reduction
32
33 in post-infarct arrhythmias.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MATERIALS AND METHODS

Experimental model

All animal experiments were performed in accordance with the *Guide for the Care and Use of Laboratory Animals* published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996).

Autologous myoblasts were injected into the infarcted area of the myocardium of Wistar rats 7 days after coronary ligation. As previously described, intramyocardial injections of a total of $10 \cdot 10^6$ autologous myoblasts were performed under direct observation via left thoracotomy[9]. Myoblast primary cultures were sourced from tibialis anterior muscles of male Wistar rats as previously described[9,10].

Lentivirus vector construction and production

A self-inactivating HIV-derived gene-transfer plasmid (pHR⁺-CMV-Cx43-W-sin18; Figure 1a) containing the cDNA for rat Cx43 downstream of the cytomegalovirus (CMV) promoter elements was kindly provided by Pr P. Meda (University of Geneva, Switzerland). As controls we used a lentivirus vector containing the same expression cassette but without the Cx43 cDNA (Null) or a lentivirus vector containing the same expression cassette and the Green Fluorescent Protein (GFP) cDNA. Lentivirus vector production was performed by the LentiVirus Production Unit (LVPU, Geneva, Switzerland).

Lentivirus vector transduction

Transduction was carried out by adding lentivirus vector to myoblast primary culture 24 hr after cell isolation (40 transducing units (TUs) /cell). Transduced cells were

1
2
3 cultured *in vitro* for 6 days before intramyocardial transplantation. Non-transduced
4
5 myoblasts and Null-transduced myoblasts served as controls.
6
7
8
9

10 ***FACS analyses***

11
12 Quantification of myoblasts and of lentivirus vector transduction efficacy in primary
13
14 culture was performed using desmin (a specific marker for muscle cells) and GFP
15
16 expression, respectively, in flow cytometry analyses. A mouse anti-human desmin
17
18 antibody (D33, Dako-Cytomation, Denmark), and a second fluorescent antibody (alexa
19
20 red anti mouse IgG; Molecular Probes) were used to detect desmin. For all GFP
21
22 analyses thresholds were chosen using a cell sample from the same primary culture
23
24 that has not been transduced with GFP-lentivirus and that did not undergo desmin
25
26 immunolabeling. Analyzes were performed using a FACSCalibur instrument (BD
27
28 Biosciences, San Jose CA, CellQuestPro software).
29
30
31
32
33
34
35
36

37 ***RNA isolation***

38
39 Total RNA was isolated from myoblasts and from myocardial tissue injected with
40
41 myoblasts, using a RNeasy Mini kit (QIAGEN) and a RNeasy fibrous tissue Mini kit
42
43 (QIAGEN), respectively. DNase treatment was performed after each RNA extraction
44
45 to eliminate genomic DNA (RNase free DNase set; QIAGEN). Absence of RNA
46
47 degradation was verified by capillary electrophoresis on a 2100 Bioanalyser (Agilent).
48
49
50
51
52

53 ***Real time RT-PCR***

54
55 First-strand cDNA was synthesized from 2 µg of total RNA using the High-Capacity
56
57 cDNA Archive Kit (Applied Biosystems) and was preamplified using
58
59 TaqMan[®] PreAmp Master Mix Kit (Applied Biosystems). On-line PCR was performed
60

1
2
3 with the following primers: desmin (Rn00574732_m1), and Cx43 (Rn01433957_m1).
4
5 Fluorogenic TaqMan probes were labeled on the 5'-end with the fluorescent reporter
6 dye 6-carboxyfluorescein (FAM[®], Applera), and on the 3'-end with non-fluorescent
7 quencher (Applied Biosystems). Data were collected with instrument spectral
8 compensations by the Applied Biosystems SDS 2.3 software and analyzed using the
9 threshold cycle (C_T) relative quantification method. Fluorescence levels were
10 normalized to the hypoxanthine guanine phosphoribosyl transferase (HPRT,
11 Rn01527838_g1), used as reference gene. Specific mRNA quantifications were
12 performed in duplicate. Absence of DNA contamination in RNA samples was verified
13 by performing real time PCR on RNA samples that were not reverse transcribed. All
14 data were averaged and then used for the $2^{-\Delta CT}$ calculation. $2^{-\Delta CT}$ corresponds to the
15 ratio of each gene expression *versus* HPRT.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 ***Immunolabeling***

35
36 Serial cryosections (10 μ m) were performed 2 weeks after myoblast transplantation. A
37 mouse monoclonal antibody against the fast skeletal myosin heavy chain (clone My32,
38 NCL-MHCf, Novocastra) and a rabbit polyclonal antibody against Cx43 (Zymed
39 Laboratories, USA) were used for identification of differentiated myotubes and Cx43,
40 respectively.
41
42
43
44
45
46
47
48
49

50 ***Ex vivo intramural electrophysiologic recordings***

51
52 Animals were sacrificed 2 weeks after autologous myoblast transplantation by
53 pentobarbital injection (100mg/kg ip; Pentobarbital sodique[®], Cerva Santé Animale).
54
55 After heparin injection (3750 UI/kg ip; Héparine Choay), hearts were harvested for
56
57
58
59
60
Langendorff perfusion at 37°C with a Krebs modified solution (NaCl, 118.3 mM;

1
2
3 KCl, 3.8 mM; MgSO₄, 1.2 mM; NaHCO₃, 25 mM; KH₂PO₄, 1.2 mM;
4
5 glucose, 11.1 mM; CaCl₂, 1.25 mM), saturated with carbogen (O₂ 95% and CO₂ 5%).
6
7 Monophasic action potentials (MAPs) were recorded during sinus rhythm (250ms) at
8
9 different sites of the myocardium (in the healthy myocardium, in the infarct border
10
11 zone and in the transplanted area of the infarct). These different sites were probed
12
13 serially with a single MAP sharp, tungsten needle-electrode that was isolated except at
14
15 the tip, as previously described [11]. Recordings in the tibialis muscle were performed
16
17 *in situ* from a nerve/tibialis muscle preparation. The nerve was stimulated and the
18
19 same MAP-electrode was inserted in the tibialis. Trains of 1 ms stimuli (S1-S1 250ms)
20
21 were applied to the nerve and the MAPs were recorded. Because the nerve was
22
23 stimulated, no pacing artifacts were present. Because the tip was in the extracellular
24
25 space, it also recorded extracellular potentials [12].
26
27
28
29
30
31
32
33

34 ***In vivo programmed electrical stimulation***

35
36 Ventricular electrical instability related to cell transplantation was evaluated in all
37
38 groups using the PES procedure, as described previously[9]. Briefly, an epicardial
39
40 electrode was tied to the viable left ventricular myocardium during surgery for
41
42 coronary ligation. For PES stimulation, animals were sedated with etomidate
43
44 (8 mg/kg ip; Hypnomidate[®], Janssen-Cilag) and pentobarbital (40 mg/kg ip). The distal
45
46 tip of the epicardial electrode was externalized to be used as the negative lead. Another
47
48 electrode was placed on the thorax to be used as the positive lead, allowing unipolar
49
50 stimulation (UHS 20, Biotronik). Surface six-lead ECGs were recorded for monitoring
51
52 and later analyses. Standard criteria were used for interval measurements (RR, PR,
53
54 QRS and QT). For further comparison between groups, QT interval were corrected
55
56 using bot Fredericia and Bazett fomulas ($QTc(F) = QT / (RR/150)^{1/3}$ and $QTc(F) = QT /$
57
58
59
60

1
2
3 (RR/150)^{1/2} respectively; Table I). Standard clinical PES protocols were used,
4 including single, double and triple extrastimuli applied under spontaneous rhythm or
5 following a train of 9 stimuli at 100-ms drive cycle length. The coupling interval of the
6 last extrastimulus was decreased to the ventricular effective refractory period (VERP).
7
8 Protocols were interrupted if sustained ventricular tachycardia (VT) was induced.
9
10 Sustained VT was defined as fast ventricular rhythm of 15 or more beats, according to
11 the Lambeth Conventions[13].
12
13
14
15
16
17
18
19
20
21

22 *Data Analyses*

23
24 Data were expressed as mean±SEM and frequencies (expressed as percentages).
25
26 Statistical analyses were performed using MedCalc 9.1 software. Real time RT-PCR
27 data and cell count data were assessed using the Student t-test. Occurrences of
28 sustained VT were compared with Cox's model and were analyzed as failure time data
29 (rats without event were considered as censored). The assumption of proportional
30 hazards between groups was confirmed, and the group was the unique covariate
31 selected in the Cox's model. Overall mortality between groups was compared using
32 Fisher's exact test. ECG parameters (P, RR, PR, QRS, QT and QTc and VERP values)
33 were assessed by a linear mixed model with random slope and intercept in the control,
34 Null, and Cx43 groups. The fixed effects were the group and the time. Interaction
35 between group and time was tested but not included in the model (not significant). The
36 power of the study was 0.40 for all statistical analysis. A p-value <0.05 was considered
37 significant.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

RESULTS

In vitro Cx43 overexpression

A lentivirus vector was used to overexpress Cx43 in rat myoblast primary cultures *ex vivo*, prior to autologous intramyocardial injection (Figure 1a). As controls we used lentivirus vectors containing an empty expression cassette (Null) or the Green Fluorescent Protein (GFP) cDNA. Efficacy of lentivirus transduction was evaluated *in vitro* using flow cytometry analyses for both GFP and desmin after GFP lentivirus vector transduction. GFP was expressed by 50% of the desmin positive cells, suggesting that 50% myoblasts expressed the transgene before transplantation (Figure 1b). The transduction rate of non-myoblast contaminating cells (i.e. GFP+ desmin – cells) was $16.3\pm 4.1\%$ (Figure 1b). Seven days after Cx43 or Null lentivirus transduction, cell counts and desmin expression levels were similar in both Null- and Cx43-transduced myoblasts, whereas Cx43 expression level was 2.5 fold higher in Cx43- than in Null-transduced myoblasts ($p<0.05$), showing that Cx43 overexpression did not alter myoblast expansion (Figure 2a).

To evaluate exogenous Cx43 expression due to Cx43 lentivirus vector transduction, we used gene expression quantification of the post-transcriptional regulatory element Woodchuck hepatitis virus (Wpre), that is located within the expression cassette of the lentivirus vector in 3' of the Cx43 cDNA and proximal to the polyadenylation signal (Figure 1a). Wpre gene expression was detected only in Cx43-transduced myoblasts 6 days after Cx43- and Null-transduction (Figure 2b). In Cx43-transduced myoblasts, total Cx43 gene expression level correlated with Wpre expression level ($R^2=0.8710$; Figure 2b). Finally, *in vitro* time-course studies demonstrated that Cx43 expression remained at least 2.5 fold higher in Cx43-transduced myoblasts than in Null-transduced myoblasts ($p\leq 0.05$, Figure 2c) for at least 35 days after Cx43 transduction.

1
2
3 Moreover, in Cx43-transduced myoblasts, Wpre gene expression remained stable. In
4
5 view of these results, Wpre was used as a marker to detect exogenous Cx43 expression
6
7 *in vivo* after intramyocardial myoblast transplantation.
8
9

10 11 12 ***In vivo* Cx43 overexpression**

13
14 Seven days after coronary ligation, rats were randomized into 3 groups: a Control
15
16 group injected with autologous myoblasts, a Null group injected with autologous
17
18 myoblasts transduced with the Null lentivirus vector, and a Cx43 group injected with
19
20 autologous myoblasts transduced with the Null lentivirus vector, and a Cx43 group injected with
21
22 autologous myoblasts transduced with the lentivirus vector encoding Cx43.
23

24
25 Using real time RT-PCR, Wpre gene expression was detected in 9/9 hearts injected
26
27 with Cx43-transduced myoblasts up to 35 days after their *in vivo* injection (Figure 3a),
28
29 suggesting that Cx43-transduced muscle cells overexpressed Cx43 *in vivo*. Two weeks
30
31 after Cx43-transduced myoblast transplantation, Cx43 protein was detected in
32
33 cryosections of infarcted myocardium in cells expressing fast skeletal myosin heavy
34
35 chain (Figures 3b-h), suggesting that *ex vivo* Cx43 lentivirus vector transduction lead
36
37 to *in vivo* Cx43 protein expression in differentiated myotubes.
38
39
40
41
42

43 44 **Electrophysiological analyses**

45
46 PES was performed at 1, 2, 3 and 4 weeks after intramyocardial myoblast
47
48 transplantation. No differences between groups were observed in ECG parameters
49
50 prior to the first PES procedure (week 1). Neither standard ECG measurements nor
51
52 VERP at 100-ms pacing cycle length were significantly altered by the repeated PES
53
54 procedures (Table I), suggesting that lentivirus vector transduction (in Null group) or
55
56 Cx43 overexpression (in Cx43 group) in transplanted myoblasts did not modify ECG
57
58 parameters. Overall the percentage of rats that underwent at least one arrhythmia event
59
60

1
2
3 during one of the PES were similar between groups (58%, 64% and 48% of animals in
4
5 the Control (n=12), Null (n=14) or Cx43 (n=23) group, respectively, Cox's model,
6
7 p=0.92, Figure 4a). Additionally, the percentage of newly inducible rats did not differ
8
9 among groups (Figure 4b). In each group, ECG parameters of rats that underwent
10
11 sustained VT during PES did not differ from those that did not show sustained VT (not
12
13 illustrated). Mortality was similar in Control, Null or Cx43 groups (42%, 50%, 43%,
14
15 respectively, p=0.87).
16
17
18
19

20 21 22 *Ex vivo measurements of intramural monophasic action potentials (MAPs)* 23

24 To evaluate electrical coupling between Cx43-overexpressing myoblasts and host
25
26 cardiomyocytes, *ex vivo* intramural monophasic action potential (MAP) recordings
27
28 were performed 14 days after myoblast injection in Langendorff-perfused hearts, using
29
30 a tungsten electrode that recorded both local MAP and remote electrical activity. For
31
32 each rat, MAPs were recorded during sinus rhythm at 7 different sites (1 located in the
33
34 right ventricle and 6 located in the left ventricle). Control included recordings from rat
35
36 tibialis muscle (Figure 5a) and from healthy non-infarcted myocardium (Figure 5b). A
37
38 total of 16 rats were evaluated, 6 in the Cx43 and in the Null groups, and 4 in the
39
40 Control group. Recordings in the infarct solely showed the remote signal of healthy
41
42 myocardium in both Null and Cx43 groups in 9/16 animals (Figures 5c,d). In 5/16 rats
43
44 monophasic action potentials (MAPs) were recorded with average duration of
45
46 52.9±4.6ms, while in 2/16 rats significantly shorter MAPs were recorded of 2.8±1.9ms
47
48 (p<0.001, Figures 5e,f, and Figures 5h,i (asterisks)). These short MAPs were similar to
49
50 those recorded in rat tibialis muscle (MAP duration 3.5ms, Figure 5a,g), while the
51
52 longer MAPs recorded in the infarct compared well to MAPs recorded in healthy
53
54 cardiac muscle (MAP duration 55.1±2.4ms, p=0.96, n=16). No such short MAPs were
55
56
57
58
59
60

1
2
3 recorded in the non-transplanted area of the heart, strongly suggesting that the short
4
5 MAPs reflected electrical activity of transplanted skeletal muscle cells, while the
6
7 longer MAPs reflected electrical activity of host cardiomyocytes.
8
9

10 In myocardium transplanted with Null-transduced myoblasts, skeletal muscle cell
11
12 MAPs and myocardial electrograms were not synchronized (Figures 5e,h), suggesting
13
14 that skeletal muscle cells were not activated in synchrony with host cardiomyocytes. In
15
16 contrast, in left ventricle from the Cx43 group, skeletal muscle cells exhibited
17
18 electrical activity in synchrony with surrounding healthy myocardium (Figures 5f,i).
19
20 Multiple registrations of 2 seconds of myoblast spikes were performed from the same
21
22 location in these rats. In the Null group, the mean interval for myoblast spikes was 545
23
24 ms (range 541 – 549 ms) and for myocyte spikes was 224 ms (range 214 – 233). In the
25
26 Cx43 group, the mean interval for myoblast spikes was 225 ms. Myoblast spikes were
27
28 synchronous with myocyte activity. These results suggest that *ex vivo* Cx43 gene
29
30 transfer and expression in myoblasts enhanced electrical coupling and frequency
31
32 entrainment of skeletal muscle cells and host cardiomyocytes.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION

1
2
3
4
5
6 In this study, using an *in vivo* model of cardiac cell and gene therapy with autologous
7 myoblasts (in which arrhythmic risk related to myoblast transplantation has been
8 previously evaluated[9]), *ex vivo* Cx43 gene transfer prior to intramyocardial
9 transplantation enhances Cx43 expression and *in vivo* electrical coupling between
10 transplanted myoblasts and host cardiomyocytes. However, in our model, improved
11 electrical coupling was not sufficient to significantly decrease arrhythmogenicity
12 related to myoblast transplantation.
13
14
15
16
17
18
19
20
21

22 Several *in vitro* studies showed that in myoblast/cardiomyocyte coculture models,
23 lentiviral-mediated overexpression of Cx43 in myoblasts was sufficient to induce gap
24 junction formation between both cell types[5,14-16]. Although we did not demonstrate
25 gap junction formation in the present study, the functionality of these gap junctions
26 was demonstrated by others, using western blot analyses and *in vitro* dye transfer
27 techniques[5,15,16]. In our study, gap junction formation and functionality were
28 suggested *in vivo* by electrical coupling between skeletal muscle cells and
29 cardiomyocytes that occurred only in myocardium injected with Cx43-transduced
30 myoblasts. Cx43 overexpression in myoblasts and gap junction formation have also
31 been successfully obtained using retrovirus[15] or adenovirus[17] vectors. In contrast
32 with our present study, increased cell death was observed *in vivo* after Cx43
33 adenovirus vector transduction and cell transplantation[17]. This was clearly linked to
34 very high vector transduction rate, as usually obtained with adenovirus vectors[18] in
35 contrast to retrovirus or lentivirus vectors. In our study, 50% myoblasts were
36 transduced by the lentivirus vectors, and Cx43 expression increased only 2.5-fold as
37 compared to baseline levels, a level compatible with studies using similar gene transfer
38 conditions[15]. In one study, no Cx43 overexpression was observed after cell
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 transplantation of Cx43 retrovirus vector-transduced myoblasts, an observation that
4 was linked to promoter silencing[15]. In our study, this was clearly not the case since
5 Wpre, a regulatory element within the expression cassette, was expressed *in vivo* more
6 than 8 weeks after cell transplantation. In summary, although each vector type lead
7 *in vitro* to significant Cx43 overexpression and gap junction formation, lentivirus
8 vector transduction offered long *in vivo* expression without deleterious effects.

9
10 An *in vitro* study showed an increase in electrical coupling between cardiomyocytes
11 and myoblasts transduced with a lentivirus vector encoding Cx43 associated to a
12 reduction (but not elimination) of myoblast arrhythmogenicity[5], an hypothesis that
13 needed to be evaluated *in vivo*. Both Roell's study and ours provided evidence of
14 *in vivo* host cardiomyocyte and transplanted myoblast electrical coupling when
15 myoblasts overexpressed Cx43. In this regard, our results confirm the feasibility of
16 *ex vivo* gene transfer to modify *in vivo* electrophysiological properties of injected
17 cells[19]. The rat number in which myoblast MAPs were observed in the heart was
18 very low, most probably because MAP recordings were performed each time using one
19 single electrode and that this electrode recorded only local electrical activity.
20 Therefore the chance that the electrode was placed in close proximity with myoblasts
21 was low, as myoblast number was also probably low. Furthermore, myoblast spikes
22 might have been hidden in the upstroke of myocyte MAPs. Some myocyte MAPs in the
23 Cx43 group showed fractionated upstrokes (not shown), suggesting that myoblast
24 spikes caused fractionation of the upstroke of these myocyte MAPs. Nevertheless,
25 fractionated upstrokes were not counted, since there was no final proof that these
26 deflections were indeed myoblast spikes. MAP recordings were performed at a pacing
27 cycle length of 250 ms. This cycle length was chosen because this is the rat normal
28 spontaneous sinus cycle length. Evaluating the level of electrical coupling between
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 transduced myoblasts and cardiomyocytes *in vivo* was not possible by changing pacing
4 rate. Conduction is determined by 3 parameters (excitability, cell-to-cell coupling and
5 myocardial architecture), and it is not possible to determine the contribution of a
6 single parameter by changing stimulation frequency. In addition, in remodeled
7 infarcted myocardium, all three parameters are changed. If conduction delay increased
8 between myoblasts and cardiomyocytes at a higher stimulation frequency it is unclear
9 whether this would be due to an inadequate coupling between host and donor cells, a
10 reduced coupling between cardiomyocytes, impaired sodium current of the
11 cardiomyocytes or the changed myocardial architecture.

12
13
14
15
16
17
18
19
20
21
22
23
24
25 In contrast to Roell's study, electrical coupling was not sufficient to significantly
26 decrease arrhythmogenicity related to myoblast transplantation in a clinically relevant
27 model combining gene and autologous cell therapy. This result highlights the
28 differences between the *in vivo* study by Roell *et al* and ours, including the animal
29 model and the level of Cx43 overexpression in transplanted cells. Although the type of
30 injury may have an impact on arrhythmia triggering, arrhythmias associated to cell
31 therapy were evaluated in different models of myocardial injury (cryolesion[8],
32 ischemia/reperfusion[20] or even pharmacological models[21]). This suggests that
33 myoblast-induced arrhythmias are not dependent from the myocardial infarction
34 model. As in Roell's study, we did not evaluate spontaneous ventricular
35 tachyarrhythmias, because their frequency is low in rodents[9]. Although in Roell's
36 study VT frequency was 100% in the myocardial infarction model, VT frequency was
37 60% in ours (a result similar to that of our previous study, confirming the
38 reproducibility of our model), probably because we counted only VT>15 beats.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1
2
3 scar of 25+3% of the left ventricle 7 weeks after coronary ligation[9], an infarct size
4
5 comparable to that in other studies using the same animal model[22]. Finally, as
6
7 mentioned above in our study only 50% transduced myoblasts expressed Cx43,
8
9 inducing an increase of the overall Cx43 expression only 2.5 fold as compared to
10
11 baseline levels. Because Roell *et al.* used myoblasts from a genetically modified
12
13 mouse overexpressing Cx43, both percentage of Cx43-overexpressing myoblasts and
14
15 Cx43 expression level may have been significantly higher, favoring extensive
16
17 electrical coupling between myoblasts and cardiomyocytes. Importantly, only
18
19 frequency but not waveform entrainment (typical for low coupling between cells with
20
21 different intrinsic action potential waveforms) was observed in our study, suggesting
22
23 that electrical coupling was too low to significantly affect the electrical stability of the
24
25 heart. It has also been suggested that the occurrence of arrhythmias depends on cell
26
27 distribution within the infarcted area, an hypothesis that was not confirmed in a recent
28
29 study on rabbits[23]. Notably, in the transgenic mouse study, electrical stability
30
31 occurred even in animals whose stem cell grafts were physically isolated from the
32
33 native myocardium. Finally, because myoblasts do not transdifferentiate into
34
35 cardiomyocytes and because their action potential duration remains significantly
36
37 shorter than host cardiomyocytes[24], an electrical coupling between both cell types
38
39 might induce locally heterogeneous distribution of action potential duration, another
40
41 risk factor for arrhythmia[1]. Although this potential adverse effect has not been
42
43 detected *in vitro* or in rodent models, because early preclinical studies did not reveal
44
45 the tendency of myoblasts to induce life-threatening arrhythmias such hypothesis
46
47 needs to be evaluated in larger animal models.
48
49
50
51
52
53
54
55
56
57 Our study has some limitations. First, we did not correlate the injected-cell number
58
59 with arrhythmia inducibility, and Cx43 overexpression might have increased *in vivo*
60

1
2
3 cell engraftment and/or proliferation as compared to engraftment of Null-transduced
4
5 cells. Although a dose-dependence between cell engraftment rate and arrhythmia might
6
7 be expected, results of a recent randomized double-blind clinical trial did not support a
8
9 dose-response increase in arrhythmic episodes[25]. In our study, we did not evaluate
10
11 the level of myoblast contamination with smooth muscle cells nor their level of viral
12
13 infection with Cx43 transgene. In humans and in rats, myoblast primary culture from
14
15 muscle samples does not lead to pure myoblast preparations[10, 3, 26], the culture
16
17 being contaminated mostly with fibroblasts. In Roell's study, myofibroblasts induced
18
19 arrhythmias, suggesting that if myofibroblasts contaminated myoblast culture, they
20
21 may induce arrhythmia when injected *in vivo*. Therefore we cannot rule out the
22
23 contribution to arrhythmia triggering of transduced or untransduced contaminating
24
25 cells with Cx43 lentivirus vector. In Roell's study, Cx43 was expressed under the
26
27 control of a promoter specific for myotubes. Therefore contaminating smooth muscle
28
29 cells did not overexpress Cx43 in Roell's study. Nevertheless, there was a significant
30
31 decrease in arrhythmias following injection of Cx43-overexpressing myoblasts,
32
33 suggesting that contaminating cells within myoblast preparations did not play a major
34
35 role in arrhythmias.
36
37
38
39
40
41
42

43 Finally, improvement of the heart function after myoblast transplantation was not
44
45 studied. Myoblast transplantation in the failing heart has been initially motivated by
46
47 the hope that transplanted cells would actively improve systolic contraction. It has
48
49 been shown that myoblasts could organize in fibers with contractile capacity, with the
50
51 right orientation such that their synchronous contraction would increase the heart
52
53 contraction strength. Without electrical coupling, skeletal muscle cells are incapable of
54
55 contributing to contraction. Myoblasts have been shown to improve heart function
56
57 (possibly by paracrine effect), and one important question would be to evaluate if an
58
59
60

1
2
3 enhanced electrical coupling (leading to synchronous contraction) improves efficacy of
4 myoblast therapy[24].
5
6

7
8 Although Cx43 expression level in Cx43 lentivirus vector-transduced myoblasts was
9 compatible with *in vitro* studies using similar gene transfer conditions[5], it may be
10 ineffective to restore full electromechanical coupling in an injured heart, as expression
11 of other junction proteins such as N-cadherin may also be necessary[27]. Therefore,
12 based on our present electrophysiological study we would suggest a note of caution on
13 the use of combined gene and cell therapy to prevent post-infarct arrhythmias. Current
14 technologic limitations to gene therapy, including low gene transduction and low
15 foreign gene expression may explain these results. In this regard, further studies to
16 improve gene therapy vectors will be rewarding.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Acknowledgements

Lentivirus vector production was performed by the Lentivirus vector Production Unit.

This work was supported in part by INSERM avenir grant, by the Association

Française contre les Myopathies and by the GIS-maladies rares. Sarah Fernandes was,

in part, supported by the Association Française contre les Myopathies. The authors

declare no conflict of interest.

For Peer Review

Tables

Table I: ECG parameters and VERP values

Time	Groups	ECG parameters (ms)							
		RR	P	PR	QRS	QT	QTc (B)	QTc (F)	VERP
Week 1	Control (n=14)	154±3.9	19±0.6	48±0.7	21±0.9	84±3.9	83±2.4	84±2.5	69±3.2
	Null (n=12)	158±3.6	19±0.5	50±1.6	21±0.7	83±2.8	81±2.2	82±2.2	65±3.5
	Cx43 (n=23)	156±2.9	18±0.3	48±1.5	22±1.2	84±1.7	83±1.2	84±1.3	59±1.7
Week 2	Control (n=12)	151±4.0	20±0.7	49±0.9	21±0.8	86±3.0	85±2.3	86±2.3	59±2.9
	Null (n=12)	158±4.4	19±0.5	50±1.9	21±0.5	86±2.9	84±2.5	85±2.6	65±5.6
	Cx43 (n=21)	150±2.3	18±0.3	48±1.0	20±0.6	80±1.5	80±1.8	80±1.7	62±3.5
Week 3	Control (n=9)	150±2.6	18±0.6	47±0.9	21±0.8	84±2.1	84±1.6	84±1.7	68±3.4
	Null (n=9)	152±3.4	18±0.5	48±1.3	21±0.5	84±1.9	83±1.6	84±1.6	59±4.6
	Cx43 (n=17)	149±2.8	18±0.4	48±1.0	21±0.7	80±2.2	80±2.3	80±2.2	60±2.4
Week 4	Control (n=7)	152±2.2	19±0.5	49±1.7	19±1.3	85±2.3	86±2.2	86±2.3	61±2.1
	Null (n=7)	157±4.6	20±0.4	50±1.5	22±0.7	84±1.8	83±1.5	83±1.5	52±3.6
	Cx43 (n=13)	149±3.9	18±0.5	48±1.1	21±0.8	83±1.6	83±1.2	83±1.3	61±2.4

ECG measurements were performed under sinus rhythm. Ventricular Effective Refractory Period was measured at a basic pacing cycle length (BCL) of 100ms at week 1, 2, 3 and 4 after myoblast transplantation. Abbreviations: P, P wave duration; RR, PR, QRS, QT, QTc(B) and QTc(F): RR, PR, QRS, QT intervals, QT interval corrected with Bazett formula (B) or Fredericia formula (F) respectively; VERP, Ventricular effective refractory period. All measurements were performed on lead I under general anesthesia. Results are expressed as mean±SEM.

References

1. **Smith RR, Barile L, Messina E, Marban E.** Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies. *Heart Rhythm.* 2008; 5: 880-7.
2. **Leobon B, Garcin I, Menasche P, Vilquin JT, Audinat E, Charpak S.** Myoblasts transplanted into rat infarcted myocardium are functionally isolated from their host. *Proc Natl Acad Sci U S A.* 2003; 100: 7808-11.
3. **Hagege AA, Carrion C, Menasche P, Vilquin JT, Duboc D, Marolleau JP, Desnos M, Bruneval P.** Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. *Lancet.* 2003; 361: 491-2.
4. **Rubart M, Soonpaa MH, Nakajima H, Field LJ.** Spontaneous and evoked intracellular calcium transients in donor-derived myocytes following intracardiac myoblast transplantation. *J Clin Invest.* 2004; 114: 775-83.
5. **Abraham MR, Henrikson CA, Tung L, Chang MG, Aon M, Xue T, Li RA, B OR, Marban E.** Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. *Circ Res.* 2005; 97: 159-67.
6. **Mills WR, Mal N, Kiedrowski MJ, Unger R, Forudi F, Popovic ZB, Penn MS, Laurita KR.** Stem cell therapy enhances electrical viability in myocardial infarction. *J Mol Cell Cardiol.* 2007; 42: 304-14.
7. **Antzelevitch C.** Basic mechanisms of reentrant arrhythmias. *Curr Opin Cardiol.* 2001; 16: 1-7.
8. **Roell W, Lewalter T, Sasse P, Tallini YN, Choi BR, Breitbart M, Doran R, Becher UM, Hwang SM, Bostani T, von Maltzahn J, Hofmann A, Reining S, Eiberger B, Gabris B, Pfeifer A, Welz A, Willecke K, Salama G, Schrickel JW, Kotlikoff MI, Fleischmann BK.** Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia. *Nature.* 2007; 450: 819-24.
9. **Fernandes S, Amirault JC, Lande G, Nguyen JM, Forest V, Bignolais O, Lamirault G, Heudes D, Orsonneau JL, Heymann MF, Charpentier F, Lemarchand P.** Autologous myoblast transplantation after myocardial infarction increases the inducibility of ventricular arrhythmias. *Cardiovasc Res.* 2006; 69: 348-58.
10. **Pouzet B, Vilquin JT, Hagege AA, Scorsin M, Messas E, Fiszman M, Schwartz K, Menasche P.** Intramyocardial transplantation of autologous myoblasts: can tissue processing be optimized? *Circulation.* 2000; 102: III210-5.
11. **Coronel R, de Bakker JM, Wilms-Schopman FJ, Opthof T, Linnenbank AC, Belterman CN, Janse MJ.** Monophasic action potentials and activation recovery intervals as measures of ventricular action potential duration: experimental evidence to resolve some controversies. *Heart Rhythm.* 2006; 3: 1043-50.
12. **Takei M, Sasaki Y, Yonezawa T, Lakhe M, Aruga M, Kiyosawa K.** The autonomic control of the transmural dispersion of ventricular repolarization in anesthetized dogs. *J Cardiovasc Electrophysiol.* 1999; 10: 981-9.

- 1
2
3 13. **Walker MJ, Curtis MJ, Hearse DJ, Campbell RW, Janse MJ, Yellon DM, Cobbe SM, Coker SJ, Harness JB, Harron DW, Higgins AJ, Julian DG, Lab MJ, Manning AS, Northover BJ, Parrat JR, Riemersma RA, Riva E, Russell DC.** The Lambeth Conventions: guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. *Cardiovasc Res.* 1988; 22: 447-55.
- 4
5
6
7
8
9
10 14. **Suzuki K, Brand NJ, Allen S, Khan MA, Farrell AO, Murtuza B, Oakley RE, Yacoub MH.** Overexpression of connexin 43 in skeletal myoblasts: Relevance to cell transplantation to the heart. *J Thorac Cardiovasc Surg.* 2001; 122: 759-66.
- 11
12
13
14
15 15. **Tolmachov O, Ma YL, Themis M, Patel P, Spohr H, Macleod KT, Ullrich ND, Kienast Y, Coutelle C, Peters NS.** Overexpression of connexin 43 using a retroviral vector improves electrical coupling of skeletal myoblasts with cardiac myocytes in vitro. *BMC Cardiovasc Disord.* 2006; 6: 25.
- 16
17
18
19
20 16. **Stagg MA, Coppen SR, Suzuki K, Varela-Carver A, Lee J, Brand NJ, Fukushima S, Yacoub MH, Terracciano CM.** Evaluation of frequency, type, and function of gap junctions between skeletal myoblasts overexpressing connexin43 and cardiomyocytes: relevance to cell transplantation. *FASEB J.* 2006; 20: 744-6.
- 21
22
23
24
25
26 17. **Reinecke H, Minami E, Virag JI, Murry CE.** Gene transfer of connexin43 into skeletal muscle. *Hum Gene Ther.* 2004; 15: 627-36.
- 27
28
29
30 18. **Lemarchand P, Jaffe HA, Danel C, Cid MC, Kleinman HK, Stratford-Perricaudet LD, Perricaudet M, Pavirani A, Lecocq JP, Crystal RG.** Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. *Proc Natl Acad Sci U S A.* 1992; 89: 6482-6.
- 31
32
33
34
35 19. **Rissanen TT, Yla-Herttuala S.** Current status of cardiovascular gene therapy. *Mol Ther.* 2007; 15: 1233-47.
- 36
37
38 20. **Fotuhi P, Song YH, Alt E.** Electrophysiological consequence of adipose-derived stem cell transplantation in infarcted porcine myocardium. *Europace.* 2007; 9: 1218-21.
- 39
40
41
42 21. **Chen M, Fan ZC, Liu XJ, Deng JL, Zhang L, Rao L, Yang Q, Huang DJ.** Effects of autologous stem cell transplantation on ventricular electrophysiology in doxorubicin-induced heart failure. *Cell Biol Int.* 2006; 30: 576-82.
- 43
44
45
46 22. **Fletcher PJ, Pfeffer JM, Pfeffer MA, Braunwald E.** Left ventricular diastolic pressure-volume relations in rats with healed myocardial infarction. Effects on systolic function. *Circ Res.* 1981; 49: 618-26.
- 47
48
49
50 23. **McCue JD, Swingen C, Feldberg T, Caron G, Kolb A, Denucci C, Prabhu S, Motilall R, Breviu B, Taylor DA.** The real estate of myoblast cardiac transplantation: negative remodeling is associated with location. *J Heart Lung Transplant.* 2008; 27: 116-23.
- 51
52
53
54 24. **Cohen IS, Rosen AB, Gaudette GR.** A Caveat Emptor for myocardial regeneration: mechanical without electrical recovery will not suffice. *J Mol Cell Cardiol.* 2007; 42: 285-8.
- 55
56
57
58
59 25. **Menasche P, Alfieri O, Janssens S, McKenna W, Reichenspurner H, Trinquart L, Vilquin JT, Marolleau JP, Seymour B, Larghero J, Lake S, Chatellier G, Solomon S, Desnos M, Hagege AA.** The Myoblast Autologous
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. *Circulation*. 2008; 117: 1189-200.
26. **Al Attar N, Carrion C, Ghostine S, Garcin I, Vilquin JT, Hagege AA, Menasche P.** Long-term (1 year) functional and histological results of autologous skeletal muscle cells transplantation in rat. *Cardiovasc Res*. 2003; 58: 142-8.
27. **Pedrotty DM, Klinger RY, Badie N, Hinds S, Kardashian A, Bursac N.** Structural coupling of cardiomyocytes and noncardiomyocytes: quantitative comparisons using a novel micropatterned cell pair assay. *Am J Physiol Heart Circ Physiol*. 2008; 295: H390-400.

For Peer Review

Figure legends

Figure 1: Cx43 transgene expression in myoblasts.

(a) The Cx43 lentivirus vector contained an expression cassette including the rat Cx43 cDNA under the control of the cytomegalovirus (CMV) promoter, followed by the post-transcriptional regulatory element of the woodchuck hepatitis virus (Wpre). (b) Evaluation of lentivirus vector transduction in myoblast primary culture 6 days after GFP-lentivirus vector transduction, by flow cytometry analyses: cells from primary culture that have not been transduced with GFP lentivirus and that have not been labeled for desmin were used as controls to design thresholds (non-transduced cells/Des-; top left panel). The same thresholds were further used for FACS analyses of non-transduced cells/Des+ cells (non-transduced cells with desmin immunostaining; top right panel), of GFP-transduced/Des- cells (GFP-transduced cells with no immunostaining; bottom left panel) and of GFP-transduced/Des+ cells (GFP-transduced cells with desmin immunostaining; bottom right panel).

Figure 2: Characterization of myoblast primary cultures after lentivirus vector transduction.

(a) Cell numbers (left panel) and desmin or Cx43 mRNA levels (right panel) in Null- and Cx43-transduced myoblasts (n=10 and n=9, respectively), 6 days after lentivirus vector transduction. Gene expression levels were measured using TaqMan real time RT-PCR. Desmin and Cx43 gene expression levels were corrected by HPRT gene expression levels. (b) Correlation between Cx43 and Wpre mRNA expression levels in Cx43 transduced myoblasts, 6 days after lentivirus vector transduction (n=9). (c) Cx43

1
2
3 gene expression from day 14 to day 35 post-transduction in Null- (dotted line) and
4 Cx43- transduced myoblasts (solid line, n=3 for both groups). * indicate $p<0.05$.
5
6
7
8
9

10 **Figure 3: *In vivo* Cx43 and Wpre gene expression, following *ex vivo* lentivirus**
11 **vector transduction and intramyocardial transplantation.**
12
13


14 (a) Wpre expression in myocardium transplanted with Cx43 transduced myoblasts. (b-
15 h) Section of left ventricle transplanted with Cx43-transduced myoblasts, in
16 fluorescent microscopy (b to e) and in confocal microscopy (f to h), using
17 immunolabeling against the fast skeletal myosin heavy chain (b and f) and Cx43 (c and
18 g). Cell nuclei were labeled with DAPI (d). (e) Superposition of the b-d panels. (h)
19 Superposition of the f and g panels. Cryosections were performed within the infarcted
20 area, 14 days after myoblast transplantation.
21
22
23
24
25
26
27
28
29
30
31
32
33

34 **Figure 4: Ventricular hyperexcitability of the myocardium after myoblast**
35 **transplantation.** Rats with myocardial infarction underwent *in vivo* Programmed
36 Electrical Stimulation (PES) procedures at 1, 2, 3 and 4 weeks after myoblast
37 transplantation. (a) Percentage of Control, Null and Cx43 rats with at least one episode
38 of sustained ventricular tachycardia (VT) during one of the PES procedures ($p=0.92$,
39 Cox's model). (b) Percentage of rats with first episode of sustained VT between week
40 1 and 4 after myoblast transplantation.
41
42
43
44
45
46
47
48
49
50
51
52

53 **Figure 5: *Ex vivo* intramural electrophysiological recordings.** Recordings were
54 performed using a sharp, tungsten needle electrode that recorded both local
55 Monophasic Action Potentials (MAPs) and remote electrograms. (a) MAPs from rat
56 tibialis anterior muscle (paced at 250-ms intervals); stars indicate fast spikes of 5 to
57
58
59
60

1
2
3 10ms length, typical for skeletal muscle. (b) MAPs from healthy myocardium in the
4
5 left ventricular free wall. Diamonds indicate typical rat cardiac MAPs of 80ms
6
7 duration. (c,d) Electrograms within the infarcted myocardium area (triangles), 14 days
8
9 after intramyocardial transplantation of Null-transduced myoblasts (c) or of Cx43-
10
11 transduced myoblasts (d). The MAP-needle only recorded the electrograms of remote
12
13 ventricular activity, as indicated by the triangles. (e,f) MAPs and electrograms from
14
15 the same infarcted regions as in c and d, but in the transplanted area. Asterisks and
16
17 triangles indicate MAPs from skeletal muscle cells and electrograms from remote non-
18
19 infarcted myocardium, respectively. Note the synchrony between MAPs from skeletal
20
21 muscle cells (asterisks) and ventricular electrograms (triangles) in the Cx43 group.
22
23 The extracellular complex (triangle) in tracing f was remote. The small deflection prior
24
25 to the MAP signal (arrows) suggests that myocardial activation preceded myoblast
26
27 activation, which suggests, but does not prove, that myocytes drove the myoblasts. (g,
28
29 h, i) enlargement of the recordings a, e and f, respectively. (j) higher enlargement of
30
31 the recording f/i.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Figure 1



Cx43 transgene expression in myoblasts.
190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 2



Characterization of myoblast primary cultures after lentivirus vector transduction.
190x254mm (300 x 300 DPI)

Figure 3





Figure 3: In vivo Cx43 and Wpre gene expression, following ex vivo lentivirus vector transduction and intramyocardial transplantation.
108x170mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 4



Ventricular hyperexcitability of the myocardium after myoblast transplantation.
190x254mm (300 x 300 DPI)

Figure 5



190x254mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60